Satellos Bioscience Inc T.MSCL

Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > Ranked #1

<< Previous

Bullboard Posts

Next >>

Comment by nozzpackon May 23, 2023 1:41pm

312 Views

Post# 35460569

RE:RE:Ranked #1

This will be a 25 bagger if that small molecule drug with the potential to regenerate functional muscle is successful as it will have many advantages and benefits for patients muscular dystrophies.

So far, experimental results are very promising worthy of its IDP rating.

The ride upwards will be very rewarding..

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages